Allergan acquires biotech Retrosense for $60 million
September 7, 2016Research and Development, Sales and Marketing Allergan, Retrosense, acquisition
Allergan has announced that it has acquired Retrosense, a biotech focused on novel gene therapy approaches to restore vision in …
Antitrust investigation launched into Mylan and the EpiPen scandal
September 7, 2016Research and Development, Sales and Marketing Mylan, US, antitrust, epipen, investigation, lawmakers, scandal
The New York attorney general has commenced an investigation into Mylan Pharmaceuticals, after an initial review indicated that the company …
European Commission approves new RA treatment from BMS
September 6, 2016Research and Development, Sales and Marketing BMS, Bristol-Myers Squibb, EMA, EU, Orencia, RA, abatacept, approval, rheumatoid arthritis
Bristol-Myers Squibb has received approval from the European Commission for rheumatoid arthritis (RA) treatment Orencia (abatacept), making it the first …
Bayer takes another shot at Monsanto acquisition
September 6, 2016Manufacturing and Production, Sales and Marketing Bayer, acqusition, monsanto
Bayer has made another move to acquire US-based Monsanto, raising the price it is prepared to pay in an effort …
Eisai “cannot understand” German agency’s recommendation to reject Halaven
September 6, 2016Manufacturing and Production, Research and Development Eisai, Germany, Halaven, IQWIG, german
Eisai has issued a statement to declare their “bewilderment” following a decision from the German Institute for Quality and Efficiency …
Taiho invests in Arcus Biosciences as part of $70 million deal
September 6, 2016Manufacturing and Production, Sales and Marketing Arcus, investment, taiho
Taiho Ventures has invested in California-based Arcus Biosciences alongside GV, Invus, DROIA Oncology Ventures and Stanford University as part of …
Horizon and Fulcrum Therapeutics form CRISPR collaboration
September 6, 2016Manufacturing and Production, Research and Development Horizon Discovery, crispr, fulcrum, fulcrum therapeutics, gene editing, horizon, rare diseases
Horizon Discovery has announced that it has entered into a partnership with Fulcrum Therapeutics to utilise Horizon’s CRISPR-based screening platform …
Non-invasive ventilation touted for COPD treatment at respiratory meeting
September 6, 2016Manufacturing and Production, Research and Development COPD, resmed
ResMed has presented results at the European Respiratory Society international congress, touting home non-invasive ventilation (NIV) as part of a …
Takeda secures $312 million zika vaccine development contract
September 5, 2016Manufacturing and Production, Research and Development, Sales and Marketing Takeda, US government, Zika, world health organization
Takeda has announced that it has been granted a $312 million contract from the US government to develop an inactivated, …
Clinton announces plan to tackle “unjustified price hikes”
September 5, 2016Sales and Marketing Drug pricing, Shkreli, US, clinton, generic drugs, president, price hikes
US Presidential candidate Hillary Clinton has outlined a wide-ranging set of proposals to tackle what she calls the “unjustified price …
GSK announce positive results for chronic obstructive pulmonary disease treatment
September 5, 2016Manufacturing and Production, Research and Development, Sales and Marketing GlaxoSmithKline, Innoviva, Revlar Ellipta, chronic obstructive pulmonary disease
GlaxoSmithKline and its partner Innoviva have announced that its Relvar Ellipta achieved positive results in its COPD Salford lung study …
MSD drops osteoporosis trial drug due to stroke risk
September 5, 2016Research and Development, Sales and Marketing MSD, Merck, Odanacatib, osteoporosis, stroke
MSD, known as Merck in the US and Canada, has announced that it has finally decided to discontinue the development …
AZ’s first respiratory biologic meets primary endpoints in Phase III trials
September 5, 2016Research and Development, Sales and Marketing AstraZeneca, asthma, benralizumab, biologic, respiratory, severe asthma
AstraZeneca has presented Phase III data at the European Respiratory Society (ERS) international congress which shows that trial biologic benralizumab …
Top ten stories in the pharmaceutical industry this week
September 2, 2016Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing pharmafile.com, top ten
As Mylan is left reeling from the backlash on its EpiPen price increase in the US, many lost their jobs …
FDA fast track designation for Biogen’s investigational Alzheimer’s treatment
September 2, 2016Medical Communications, Research and Development Alzheimer's, Alzheimer’s, Biogen, FDA, aducanumab, fast track
Biogen has announced that its investigational Alzheimer’s disease treatment aducanumab has been granted fast track designation by the FDA. The …
Amgen’s leukaemia treatment given FDA thumbs up for use in paediatric patients
September 2, 2016Medical Communications, Sales and Marketing Amgen, FDA, blincyto, leukaemia
Amgen has announced that the FDA has approved the supplemental Biologics License Application for Blincyto (blinatumomab) in the treatment of …
NICE recommends Bayer’s Xofigo for prostate cancer treatment
September 2, 2016Medical Communications, Sales and Marketing Bayer, NICE, approval, prostate cancer, recommendation, xofigo
NICE has issued final draft guidance recommending Bayer’s Xofigo (radium-223 dichloride) for the treatment of prostate cancer. Previously, the drug …
ABPI welcomes Roche back into the fold eight years after suspension
September 1, 2016Medical Communications, Research and Development ABPI, Roche, rejoin, suspension
Less than a decade after the company was suspended, Roche has now successfully re-joined the Association of the British Pharmaceutical …
Sepha is fast packing with a new EZ Blister upgrade.
September 1, 2016Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing
Packaging Equipment Specialist, Sepha, has released a functional upgrade for one of its original products, EZ Blister, the lab scale …
Cloud on the horizon: Cloud computing and the clinical trial
September 1, 2016Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Cloud Computing, ICON, clinical trials, ibm
Originally published in the September edition of Pharmafocus, Matt Fellows investigates how cloud computing may just be the answer the …
Latest content
The evidence bar impacting UK medical cannabis access
Addressing the rheumatic disease diagnostic gap in primary care
